However, future studies performed on transgenic mouse models of AD and on the post-mortem brain of AD patients might shed more light in the implication of PD-linked LRRK2 to AD pathogenesis and could contribute to dissecting novel pathological mechanisms for pharmacological intervention to limit AD progression. This evidence concerns the gene LRRK2 and Alzheimer disease.